In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

The updates included data on multiple drug candidates, such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight was on BNT327, particularly after ...

Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...

The updates included data on multiple drug candidates, such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight was on BNT327, particularly ...

BioNTech's updates included promising data from phase II and phase I/II trials for BNT327/PM8002, an anti-VEGF-A/PD-L1 bispecific. The analyst highlighted the need for BioNTech to diversify beyond ...

BioNTech's updates included promising data from phase II and phase I/II trials for BNT327/PM8002, an anti-VEGF-A/PD-L1 bispecific. The analyst highlighted the need for BioNTech to diversify beyond its ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...